At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
|Articles|May 2, 2003
- Pharmaceutical Technology-05-02-2003
- Volume 27
- Issue 5
Drug Safety in the Limelight
Author(s)Jill Wechsler
FDA resolves the bar code labeling debate, releases its GMP requirements for dietary supplements, and proposes a comprehensive adverse-event reporting system.
Advertisement
Articles in this issue
over 23 years ago
May 2003over 23 years ago
Outsourcing Outlookover 23 years ago
The Square Root of N Plus One Sampling Ruleover 23 years ago
Particle Attrition by Particle?Surface Friction in DryersAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
2
PharmTech’s Weekly Roundup—September 25, 2026
3
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
4
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
5